Mohammad Hirmand
Director/Board Member at AADI BIOSCIENCE, INC.
Profile
Dr. Mohammad Hirmand, MD, is a Chief Medical Officer & Executive Vice President at Turning Point Therapeutics, Inc. Dr. Hirmand was previously employed as a Vice President-Clinical Development by Medivation LLC (California), an Associate Director-Clinical Research by Amgen, Inc., a Senior Director-Clinical Development by ARCA biopharma, Inc., a Manager-Market Development & Product Evaluation by Innoviva, Inc., a Senior Director-Clinical Development by Nuvelo, Inc., a Chief Medical Officer by Peloton Therapeutics, Inc., a Director-Oncology Development by SuperGen, Inc., a Principal by Theravance Biopharma US, Inc., and a Manager-Clinical Data by Tularik, Inc. He received his undergraduate degree from Cornell University and a doctorate degree from Harvard Medical School.
Mohammad Hirmand active positions
Companies | Position | Start |
---|---|---|
AADI BIOSCIENCE, INC. | Director/Board Member | 2023-03-26 |
Avenzo Therapeutics, Inc.
Avenzo Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avenzo Therapeutics, Inc. is a biotechnology company that operates in the field of therapeutics. The company is based in San Diego, CA. The company was founded by Mohammad Hirmand and the CEO is Athena M. Countouriotis. | Founder | - |
Former positions of Mohammad Hirmand
Companies | Position | End |
---|---|---|
TURG POIN | Chief Tech/Sci/R&D Officer | 2022-07-31 |
PELOTON THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2019-12-30 |
MEDIVATION INC | Chief Operating Officer | 2015-09-30 |
Theravance Biopharma US, Inc.
Theravance Biopharma US, Inc. Miscellaneous Commercial ServicesCommercial Services Theravance Biopharma US, Inc. operates as a biopharmaceutical company. The firm serves in the areas of inflammation and immunology, drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol. The company is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
ARCA BIOPHARMA, INC. | Corporate Officer/Principal | - |
Training of Mohammad Hirmand
Cornell University | Undergraduate Degree |
Harvard Medical School | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 4 |
---|---|
AMGEN INC. | Health Technology |
INNOVIVA, INC. | Health Technology |
ARCA BIOPHARMA, INC. | Health Technology |
AADI BIOSCIENCE, INC. | Health Technology |
Private companies | 8 |
---|---|
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Health Technology |
Nuvelo, Inc. | Health Technology |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Commercial Services |
Peloton Therapeutics, Inc.
Peloton Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. Its lead drug candidate is a small molecule which targets HIF-2a, a transcription factor implicated in the development and progression of renal and other cancers. The company was founded by Steven L. McKnight in August 2010 and is headquartered in Dallas, TX. | Health Technology |
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Medivation LLC (California)
Medivation LLC (California) Pharmaceuticals: MajorHealth Technology Medivation LLC engages in the development and commercialization of novel therapies to treat serious diseases for which there are limited treatment options. The company was founded by Clarence Patrick Machado and David T. Hung in 2004 and is headquartered in San Francisco, CA. | Health Technology |
Theravance Biopharma US, Inc.
Theravance Biopharma US, Inc. Miscellaneous Commercial ServicesCommercial Services Theravance Biopharma US, Inc. operates as a biopharmaceutical company. The firm serves in the areas of inflammation and immunology, drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol. The company is headquartered in South San Francisco, CA. | Commercial Services |
Avenzo Therapeutics, Inc.
Avenzo Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avenzo Therapeutics, Inc. is a biotechnology company that operates in the field of therapeutics. The company is based in San Diego, CA. The company was founded by Mohammad Hirmand and the CEO is Athena M. Countouriotis. | Commercial Services |